For NSCLC patients whose tumors harbor mutations in EGFR, disruption of the KEAP1/NRF2 pathway is of the most recently reported mechanisms by which EGFR-tyrosine kinase inhibitors (EGFR-TKI) resistance occurs [5]. Here, KEAP1 is linked to non-small cell lung carcinoma.